<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 29 Apr 2021 23:22:36 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>这些专利药于2021年到期，各大厂商做好准备了吗？</title><link>https://mp.weixin.qq.com/s/oMgtMEIMnnYLoWNK90dZuQ</link><description></description><content:encoded><![CDATA[这些专利药于2021年到期，各大厂商做好准备了吗？]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:41:55 +0800</pubDate></item><item><title>西那卡塞：增速143%、专利期至，国内仿制再掀热潮！</title><link>https://mp.weixin.qq.com/s/zH7AjzJ4MF9fX2FUsP1PVA</link><description></description><content:encoded><![CDATA[西那卡塞：增速143%、专利期至，国内仿制再掀热潮！]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:41:55 +0800</pubDate></item><item><title>国采最新执行情况，阿比特龙采购完成度已超5000%！</title><link>https://mp.weixin.qq.com/s/-lxkJbQ3GI62LOqJKDmM1Q</link><description></description><content:encoded><![CDATA[国采最新执行情况，阿比特龙采购完成度已超5000%！]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:41:55 +0800</pubDate></item><item><title>【FDA】复杂仿制药的监管现状研究</title><link>https://mp.weixin.qq.com/s/7T1dg0paKQJrYFMbYf4pjQ</link><description></description><content:encoded><![CDATA[【FDA】复杂仿制药的监管现状研究]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:41:55 +0800</pubDate></item><item><title>第五批国采来袭，哪些企业最具竞争力？</title><link>https://mp.weixin.qq.com/s/1dxSewt4-YEJh76u96IjXw</link><description></description><content:encoded><![CDATA[第五批国采来袭，哪些企业最具竞争力？]]></content:encoded><pubDate>Wed, 28 Apr 2021 21:40:27 +0800</pubDate></item><item><title>集采、一致性评价双轮驱动，大批药品降价、撤网！</title><link>https://mp.weixin.qq.com/s/v-i-ZaTCOY2cVAxit4jBWQ</link><description></description><content:encoded><![CDATA[集采、一致性评价双轮驱动，大批药品降价、撤网！]]></content:encoded><pubDate>Wed, 28 Apr 2021 21:40:27 +0800</pubDate></item><item><title>原料无法供应，一中标品种面临暂停采购！</title><link>https://mp.weixin.qq.com/s/Gh0rjFVGUqzDyY1hoUfhbw</link><description></description><content:encoded><![CDATA[原料无法供应，一中标品种面临暂停采购！]]></content:encoded><pubDate>Wed, 28 Apr 2021 21:40:27 +0800</pubDate></item><item><title>第四十一批参比目录发布，55个新增、10个变更...</title><link>https://mp.weixin.qq.com/s/g_M7H18T_L8flXR8YY6oSw</link><description></description><content:encoded><![CDATA[第四十一批参比目录发布，55个新增、10个变更...]]></content:encoded><pubDate>Wed, 28 Apr 2021 21:40:27 +0800</pubDate></item><item><title>潜力品种Top 10排行，单抗药物一马当先！</title><link>https://mp.weixin.qq.com/s/AFkrYrCDvoNq2strEFwEyg</link><description></description><content:encoded><![CDATA[潜力品种Top 10排行，单抗药物一马当先！]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:29 +0800</pubDate></item><item><title>27个大品种联动降价，涉及齐鲁、扬子江、天晴...</title><link>https://mp.weixin.qq.com/s/gNWVZAKgGtWMCfq2HU-5Zw</link><description></description><content:encoded><![CDATA[27个大品种联动降价，涉及齐鲁、扬子江、天晴...]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:29 +0800</pubDate></item><item><title>化工巨头调价开始，涨价潮已来！停航停运，​运价暴涨450%！</title><link>https://mp.weixin.qq.com/s/X8kxm-L6STlqkn15Zbiqsg</link><description></description><content:encoded><![CDATA[化工巨头调价开始，涨价潮已来！停航停运，​运价暴涨450%！]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:29 +0800</pubDate></item><item><title>省际联盟集采再启航，注射剂「霸屏」</title><link>https://mp.weixin.qq.com/s/ho2qajDuPhat6HUYyOImig</link><description></description><content:encoded><![CDATA[省际联盟集采再启航，注射剂「霸屏」]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:29 +0800</pubDate></item><item><title>基药目录释放信号，五个重点方向值得关注！</title><link>https://mp.weixin.qq.com/s/imK7cXaJQ2Pto7k4M52alA</link><description></description><content:encoded><![CDATA[基药目录释放信号，五个重点方向值得关注！]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:29 +0800</pubDate></item><item><title>（2021.4.26）最新过评名单，5品种首家冲线...</title><link>https://mp.weixin.qq.com/s/70oFLxhNrf1NnSyFAc3FBg</link><description></description><content:encoded><![CDATA[（2021.4.26）最新过评名单，5品种首家冲线...]]></content:encoded><pubDate>Mon, 26 Apr 2021 21:41:15 +0800</pubDate></item><item><title>500品种集采步步推进，针剂药品“蜕变”成主角！</title><link>https://mp.weixin.qq.com/s/RsI95Ape04STx3e56HdVrQ</link><description></description><content:encoded><![CDATA[500品种集采步步推进，针剂药品“蜕变”成主角！]]></content:encoded><pubDate>Mon, 26 Apr 2021 21:41:15 +0800</pubDate></item><item><title>千余个药品将失去院内销售市场</title><link>https://mp.weixin.qq.com/s/693OaGsMjSTFyVTw6H0esA</link><description></description><content:encoded><![CDATA[千余个药品将失去院内销售市场]]></content:encoded><pubDate>Mon, 26 Apr 2021 21:41:15 +0800</pubDate></item><item><title>CDE：第二批已上市药品说明书增加儿童用药信息公开征求意见</title><link>https://mp.weixin.qq.com/s/xfSC3UM1I_1JSRVGkAjeTA</link><description></description><content:encoded><![CDATA[CDE：第二批已上市药品说明书增加儿童用药信息公开征求意见]]></content:encoded><pubDate>Mon, 26 Apr 2021 21:41:15 +0800</pubDate></item><item><title>「吗丁啉」优势不再，国产仿制大有接管市场之意！</title><link>https://mp.weixin.qq.com/s/jKdzMGudNgLP-ihKbykYvQ</link><description></description><content:encoded><![CDATA[「吗丁啉」优势不再，国产仿制大有接管市场之意！]]></content:encoded><pubDate>Sun, 25 Apr 2021 21:41:51 +0800</pubDate></item><item><title>美托洛尔：两种酸根，相隔大半个市场</title><link>https://mp.weixin.qq.com/s/fqB8NJJ9Z5UJKww8MnPTSA</link><description></description><content:encoded><![CDATA[美托洛尔：两种酸根，相隔大半个市场]]></content:encoded><pubDate>Sun, 25 Apr 2021 21:41:51 +0800</pubDate></item><item><title>422个药品，拟调入（出）短缺药目录</title><link>https://mp.weixin.qq.com/s/9mA1rArIli3nwU964uU2og</link><description></description><content:encoded><![CDATA[422个药品，拟调入（出）短缺药目录]]></content:encoded><pubDate>Sun, 25 Apr 2021 21:41:51 +0800</pubDate></item></channel></rss>